Floatz logo

Rivogenlecleucel

Diamond Blackfan Anemia

Bellicum PharmaceuticalsCell therapyPhase 1/2Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Diamond Blackfan Anemia cohort.

Asset / SponsorPhaseRating
Deferasirox
Novartis
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2/3BBB
Busulphan
Paul Szabolcs
Phase 2/3BBB
Cyclophosphamide
Paul Szabolcs
Phase 2/3BB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2BB

View all 24 →

Same molecule, other indications

Rivogenlecleucel is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
44 / 100
View asset →
inborn error of immunityDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →